These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 21950209

  • 1. Predicting tumour response to anti-HER1 therapy using medical imaging: a literature review and in vitro study of [18F]-FDG incorporation by breast cancer cells responding to cetuximab.
    Smith TA, Cheyne RW.
    Br J Biomed Sci; 2011; 68(3):158-66. PubMed ID: 21950209
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. EGF receptor stimulation shifts breast cancer cell glucose metabolism toward glycolytic flux through PI3 kinase signaling.
    Jung KH, Lee EJ, Park JW, Lee JH, Moon SH, Cho YS, Lee KH.
    PLoS One; 2019; 14(9):e0221294. PubMed ID: 31532771
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. 18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice.
    McLarty K, Fasih A, Scollard DA, Done SJ, Vines DC, Green DE, Costantini DL, Reilly RM.
    J Nucl Med; 2009 Nov; 50(11):1848-56. PubMed ID: 19837760
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR-detectable phosphomonoesters.
    Smith TA, Appleyard MV, Sharp S, Fleming IN, Murray K, Thompson AM.
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):473-80. PubMed ID: 23178956
    [Abstract] [Full Text] [Related]

  • 11. Influence of resistance to 5-fluorouracil and tomudex on [18F]‑FDG incorporation, glucose transport and hexokinase activity.
    Law AA, Collie-Duguid ES, Smith TA.
    Int J Oncol; 2012 Jul; 41(1):378-82. PubMed ID: 22576694
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial.
    Berger AK, von Gall C, Abel U, Delorme S, Kloor M, Ose J, Weber TF, Stange A, Haag GM, Haberkorn U, Lordick F, Jäger D.
    BMC Cancer; 2012 Mar 22; 12():108. PubMed ID: 22439666
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma.
    Niu G, Sun X, Cao Q, Courter D, Koong A, Le QT, Gambhir SS, Chen X.
    Clin Cancer Res; 2010 Apr 01; 16(7):2095-105. PubMed ID: 20215534
    [Abstract] [Full Text] [Related]

  • 17. Characterizing breast cancer xenograft epidermal growth factor receptor expression by using near-infrared optical imaging.
    Wang K, Wang K, Li W, Huang T, Li R, Wang D, Shen B, Chen X.
    Acta Radiol; 2009 Dec 01; 50(10):1095-103. PubMed ID: 19922304
    [Abstract] [Full Text] [Related]

  • 18. PET imaging of EGFR expression in nude mice bearing MDA-MB-468, a human breast adenocarcinoma.
    Sadri K, Ren Q, Zhang K, Paudyal B, Devadhas D, Rodeck U, Thakur M.
    Nucl Med Commun; 2011 Jul 01; 32(7):563-9. PubMed ID: 21572364
    [Abstract] [Full Text] [Related]

  • 19. Cetuximab: from bench to bedside.
    Vincenzi B, Zoccoli A, Pantano F, Venditti O, Galluzzo S.
    Curr Cancer Drug Targets; 2010 Feb 01; 10(1):80-95. PubMed ID: 20088790
    [Abstract] [Full Text] [Related]

  • 20. 3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition.
    Kelly CJ, Hussien K, Muschel RJ.
    Nucl Med Biol; 2012 Oct 01; 39(7):986-92. PubMed ID: 22682985
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.